GO
Loading...

Pfizer Inc

More

  • Asia shares mixed on lackluster China data Wednesday, 23 Apr 2014 | 12:06 AM ET

    TOKYO— Shares were mixed in Asia on Wednesday, as weak data from China sapped upward momentum from an overnight rally on a flurry of deals in the pharmaceutical sector. Overnight, U.S. financial data and corporate earnings helped spur gains from deals by Switzerland's Novartis with Britain's GlaxoSmithKline PLC and the Eli Lilly& Co. of the U.S.

  • April 22- At any given time, the acquisitive chief executive of Valeant Pharmaceuticals Inc is brokering multiple deal discussions and eyeing as many as 50 buying opportunities. Pearson's latest target, with help from activist investor Bill Ackman, is Allergan Inc, maker of anti-wrinkle treatment Botox.

  • Pharma deals give stocks a lift Tuesday, 22 Apr 2014 | 5:22 AM ET

    HONG KONG— World stocks fluctuated Tuesday as a Wall Street rally powered by positive earnings reports offset investor cautiousness before a report on Chinese manufacturing and possible sanctions against Russia over Ukraine.

  • Pfizer held talks with AstraZeneca: Reports     Tuesday, 22 Apr 2014 | 12:46 AM ET

    CNBC's Catherine Boyle discusses reports that U.S. drugmaker Pfizer held informal talks with pharmaceutical firm AstraZeneca about a takeover bid.

  • Valeant, Ackman make $45.6B Allergan bid Tuesday, 22 Apr 2014 | 12:03 AM ET

    NEW YORK— Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion. Each Allergan share would be exchanged for $48.30 in cash and 0.83 shares of Valeant Pharmaceuticals International Inc. common stock.

  • NEW YORK- Pfizer Inc has agreed to pay $190 million to settle a class action lawsuit alleging the pharmaceutical company took steps to delay market entry of generic versions of its epilepsy drug Neurontin, according to court documents filed on Monday.

  • Pfizer-AstraZeneca deal? Not as crazy as it sounds Monday, 21 Apr 2014 | 6:24 PM ET
    Cholesterol drugs, Crestor, left, manufactured by AstraZeneca Plc, and Lipitor, manufactured by Pfizer Inc.

    There are some solid reasons why Pfizer's reported $101 billion bid for AstraZeneca makes some sense, analysts said.

  • AstraZeneca cancer pipeline likely draw for Pfizer Monday, 21 Apr 2014 | 6:16 PM ET
    A Pfizer technician as she works at Neusentis Ltd.'s research laboratory, a unit of Pfizer Inc., in Cambridge, U.K., on Thursday, Sept. 26, 2013.

    Pfizer Inc may come back to bid for British drug company AstraZeneca Plc after its reported 60 billion pound takeover approach was rejected.

  • Final Glance: Pharmaceuticals companies Monday, 21 Apr 2014 | 6:02 PM ET

    Baxter International Inc. rose$. 34 or. 5 percent, to $73.15. Bristol-Myers Squibb Co. rose $1.05 or 2.1 percent, to $50.51. Hospira rose$. 33 or. 8 percent, to $43.17.

  • Value stocks to stay in vogue, as momentum fades Monday, 21 Apr 2014 | 5:41 PM ET

    With the wipeout in growth stocks, many investors turned their attention to big-cap and value names, and the trend is expected to continue.

  • Valeant to bid for Botox maker Allergan Monday, 21 Apr 2014 | 5:40 PM ET

    NEW YORK— Valeant Pharmaceuticals has teamed up with activist investor Bill Ackman to make a bid for Botox maker Allergan that could be worth about $40 billion. Valeant said Monday that it intends to propose a merger with Allergan using a combination of Valeant stock and cash.

  • *Netflix climbs in extended-hours trading after results. NEW YORK, April 21- U.S. stocks advanced modestly on Monday in subdued trading as investors showed hesitation in the wake of a strong rally last week and before a slew of key earnings releases this week.

  • Stocks rose on Monday after the S&P 500's largest weekly advance since July.

  • *Results from Netflix expected after the market close. NEW YORK, April 21- U.S. stocks advanced modestly on Monday as investors showed hesitation in the wake of a strong rally last week and ahead of key earnings releases. The S&P 500 posted its best week since July last week, boosted by results from such names as General Electric Co and Morgan Stanley.

  • Midday Glance: Pharmaceuticals companies Monday, 21 Apr 2014 | 1:20 PM ET

    Baxter International Inc. rose$. 35 or. 5 percent, to $73.16. Bristol-Myers Squibb Co. rose$. 62 or 1.3 percent, to $50.08. Hospira rose$. 05 or. 1 percent, to $42.89.

  • Most active New York Stock Exchange-traded stocks Monday, 21 Apr 2014 | 1:20 PM ET

    NEW YORK— A look at New York Stock Exchange 10 most-active stocks at the close of trading:. AT&T Inc. rose. 1 percent to $36.06 with 18,500,200 shares traded. Advanced Micro Devices Inc. rose 11.7 percent to $4.12 with 99,956,700 shares traded.

  • Mega pharma deal?     Monday, 21 Apr 2014 | 12:52 PM ET

    Reports over the weekend say Pfizer may have approached AstraZenaca a few months ago, but talks fizzled. CNBC's Meg Tirrell reports analysts say Pfizer has about $70 billion in cash.

  • Midday movers: Facebook, Home Depot, Pfizer & More Monday, 21 Apr 2014 | 12:05 PM ET

    Some of Monday's midday movers:

  • *Results from Netflix expected after the market close. NEW YORK, April 21- U.S. stocks rose slightly on Monday as investors found few reasons to push indexes sharply higher following a strong rally last week and ahead of key earnings releases.

  • US STOCKS-Wall St flat as investors await earnings Monday, 21 Apr 2014 | 10:51 AM ET

    *Results from Netflix expected after the market close. NEW YORK, April 21- U.S. stocks were flat on Monday ahead of key earnings releases as investors found few reasons to push indexes sharply higher following a strong rally last week. The S&P 500 posted its best week since July last week, boosted by results from such names as General Electric Co and Morgan Stanley.

Most Popular Video

Wednesday, 23 Apr 2014 | 12:32 AM ET

Eddie Tam, CIO at Central Asset Investments, says China will see a slowdown for a long time as a trade-off for avoiding a hard landing in its economy.

Tuesday, 22 Apr 2014 | 10:48 PM ET

Todd Elmer, Currency Strategist at Citi, discusses whether the currency's sharp drop following weaker-than-expected quarterly inflation data was justified.

Tuesday, 22 Apr 2014 | 10:30 PM ET

Adaire Fox-Martin, COO, Asia Pacific Japan at SAP, elaborates on the firm's "stunning results" in Southeast Asia, India and the sector of cloud computing in the first-quarter.